作者: 無(wú)政府主義者 時(shí)間: 2025-3-21 22:46 作者: shrill 時(shí)間: 2025-3-22 00:34 作者: nugatory 時(shí)間: 2025-3-22 04:45 作者: 藥物 時(shí)間: 2025-3-22 12:13 作者: Forsake 時(shí)間: 2025-3-22 16:00 作者: 牽連 時(shí)間: 2025-3-22 17:36
Adjuvant Systemic Therapy: Endocrine Therapyll breast cancers. Adjuvant endocrine therapy is a pivotal component of treatment for women with hormone receptor-positive early-stage breast cancer; it delays local and distant relapse and prolongs survival. Patients with ER- and/or PR-positive invasive breast cancers should be considered for adjuv作者: multiply 時(shí)間: 2025-3-23 00:01 作者: 矛盾 時(shí)間: 2025-3-23 01:47
Adjuvant Therapy for HER2-Positive Early Breast Cancers stories in the history of breast cancer. The development of HER-2-targeted therapies has changed the natural history of HER-2-positive breast cancer dramatically in the past two decades. Success in the metastatic setting has been subsequently translated into improved clinical outcomes for women wi作者: thrombus 時(shí)間: 2025-3-23 05:39 作者: 鉗子 時(shí)間: 2025-3-23 10:16
Adjuvant Radiation Therapy After Preoperative Chemotherapys. The use of three-field radiotherapy (RT) including the chest wall/breast and regional lymphatics after surgery in locally advanced, node-positive patients receiving neoadjuvant systemic chemotherapy is well established. Patients with clinically staged T3–T4 tumors, pathological non-complete respo作者: 鎮(zhèn)痛劑 時(shí)間: 2025-3-23 15:47 作者: HARP 時(shí)間: 2025-3-23 21:24 作者: Commonplace 時(shí)間: 2025-3-24 00:52
Neoadjuvant Hormonal Therapy in Breast Cancerally advanced breast cancer: chemotherapy or hormonal therapy. Chemotherapy can be particularly toxic for elderly postmenopausal patients, and neoadjuvant hormonal therapy (NHT) is an alternative for patients with hormone receptor-positive, locally advanced, postmenopausal breast cancer. This treatm作者: 故意 時(shí)間: 2025-3-24 03:47 作者: 哭得清醒了 時(shí)間: 2025-3-24 07:57 作者: observatory 時(shí)間: 2025-3-24 10:40
Book 20161st editioners up to speed with the latest guidelines and therapeuticregimens in breast cancer and provides and in-depth account of current and newtherapeutic approaches. ..Divided in themed parts, the book examines invasive breastcancer, pre-operative systemic therapy surgical management and recurrence amongo作者: 猛烈責(zé)罵 時(shí)間: 2025-3-24 15:59
Advances in Intelligent and Soft Computing for stage III and possibly stage II breast cancer using imaging techniques including FDG PET/CT. The workup of abnormal findings in breast cancer patients is by patient signs and symptoms including history and physical examination, laboratory tests, imaging, biopsy of suspicious finding in imaging studies, and monitoring serum markers.作者: 不能逃避 時(shí)間: 2025-3-24 21:34 作者: Priapism 時(shí)間: 2025-3-24 23:39 作者: lymphoma 時(shí)間: 2025-3-25 04:45 作者: chondromalacia 時(shí)間: 2025-3-25 08:12 作者: 歡笑 時(shí)間: 2025-3-25 14:38
Neoadjuvant Hormonal Therapy in Breast Cancerhat breast-conserving surgery (BCS) may become an option. The optimal duration of such treatments should not be less than 4 months and may be continued for as long as 8 months..?There are no studies showing benefits of neoadjuvant endocrine therapy in premenopausal patients.作者: accessory 時(shí)間: 2025-3-25 15:48 作者: LEVY 時(shí)間: 2025-3-25 21:10 作者: 媒介 時(shí)間: 2025-3-26 03:00 作者: 令人苦惱 時(shí)間: 2025-3-26 05:27 作者: 改進(jìn) 時(shí)間: 2025-3-26 11:51
Advances in Intelligent and Soft Computing, but recent data have demonstrated that breast-conserving surgery (BCS) and radiotherapy are equivalent to ALND of micro-/macrometastatic sentinel lymph nodes (SLNs). This approach will reduce the morbidity of dissection without decreasing overall survival (OS).作者: 無(wú)聊的人 時(shí)間: 2025-3-26 14:46
Surgical Treatment of Early-Stage Breast Cancerand safe surgical approaches are needed to provide local control with satisfactorily high survival..?In this chapter, we attempt to define the entity of early breast cancer and the mainstream surgical approach in light of modern achievements in the surgical treatment of breast cancer.作者: Terminal 時(shí)間: 2025-3-26 18:26
Evaluation of Axillary Nodes, but recent data have demonstrated that breast-conserving surgery (BCS) and radiotherapy are equivalent to ALND of micro-/macrometastatic sentinel lymph nodes (SLNs). This approach will reduce the morbidity of dissection without decreasing overall survival (OS).作者: 無(wú)禮回復(fù) 時(shí)間: 2025-3-26 23:16 作者: 敏捷 時(shí)間: 2025-3-27 03:51
Breast Reconstructionisions regarding the timing, type, and extent of reconstruction. The gold standard for breast cancer care includes an integrated multidisciplinary team approach comprising surgical oncologists, medical oncologists, radiation oncologists, oncology nurses, and plastic surgeons.作者: Arb853 時(shí)間: 2025-3-27 05:18 作者: BULLY 時(shí)間: 2025-3-27 10:20 作者: 參考書(shū)目 時(shí)間: 2025-3-27 16:13
Biopsy Techniques in Non-palpable or Palpable Breast Lesionsc benign lesions or when coring biopsy tools fail to provide adequate diagnostic information and material. Ductoscopy, which was initially developed as a tool to investigate pathological nipple discharge, is an evolving technology that may have an increasing role in research and prevention as tools 作者: 樂(lè)器演奏者 時(shí)間: 2025-3-27 19:29
Staging of Breast Cancerof ongoing TNM staging to determine whether to apply systemic therapy based on anatomic prognosis. Although multigene expression assays, such as the 70-gene prognostic signature or Oncotype DX tests, may provide additional prognostic and predictive information beyond anatomic TNM staging and ER/PR a作者: 截?cái)?nbsp; 時(shí)間: 2025-3-27 22:59 作者: 巨頭 時(shí)間: 2025-3-28 04:17
Adjuvant Systemic Chemotherapy for HER2-Negative Diseasegimen depends on the intrinsic subtype. Multigene expression array profiling is not always required for subtype definition after clinicopathological assessment. Young age, grade 3 disease, lymphovascular invasion, one to three positive nodes, and large tumor size are not adequate features to omit mo作者: Muffle 時(shí)間: 2025-3-28 09:31 作者: infringe 時(shí)間: 2025-3-28 10:34
Adjuvant Radiation Therapy After Preoperative Chemotherapynal treatment), selected patients (cT1–2, cN1, and >40 years old) with pathological complete response (pCR) (ypT0, ypTis, ypN0) and non-triple-negative histology after neoadjuvant chemotherapy could possibly be followed without postmastectomy radiotherapy (PMRT) and without regional irradiation in a作者: Somber 時(shí)間: 2025-3-28 15:07
Preoperative Therapy for Operable Breast CancerC provides an ideal setting in which the responsiveness of a given treatment can be observed and provides relevant information on the biology of the tumor by enabling biomarker analysis. Accumulating data on the strong association with survival and pathological complete response (pCR) may lead to a 作者: vertebrate 時(shí)間: 2025-3-28 20:35
Systemic Therapy for Inflammatory Breast Cancerl rates range from 46 % to 61 % and 15-year survival rates vary between 20 % and 30 %. The response to primary chemotherapy is a strong indicator of survival. The 15-year survival rate is 44 % in patients who achieve a pathological complete response after primary chemotherapy. In this chapter, preop作者: OREX 時(shí)間: 2025-3-29 00:11 作者: Indecisive 時(shí)間: 2025-3-29 05:49
y perspective on breast diseases.Contributions from an international team of experts present invaluable insightinto clinical practice across different settings. Covering both theoretical andpractical aspects of978-3-319-26012-9作者: Ingrained 時(shí)間: 2025-3-29 10:56 作者: Archipelago 時(shí)間: 2025-3-29 12:44
Advances in Intelligent and Soft Computingof ongoing TNM staging to determine whether to apply systemic therapy based on anatomic prognosis. Although multigene expression assays, such as the 70-gene prognostic signature or Oncotype DX tests, may provide additional prognostic and predictive information beyond anatomic TNM staging and ER/PR a作者: –LOUS 時(shí)間: 2025-3-29 18:32 作者: 少量 時(shí)間: 2025-3-29 23:36
Alaa Sagheer,Saleh Aly,Samar Antergimen depends on the intrinsic subtype. Multigene expression array profiling is not always required for subtype definition after clinicopathological assessment. Young age, grade 3 disease, lymphovascular invasion, one to three positive nodes, and large tumor size are not adequate features to omit mo作者: blackout 時(shí)間: 2025-3-30 01:57 作者: 琺瑯 時(shí)間: 2025-3-30 05:12 作者: Contracture 時(shí)間: 2025-3-30 11:43
Krzysztof Dobosz,Klaudiusz StawskiC provides an ideal setting in which the responsiveness of a given treatment can be observed and provides relevant information on the biology of the tumor by enabling biomarker analysis. Accumulating data on the strong association with survival and pathological complete response (pCR) may lead to a 作者: osculate 時(shí)間: 2025-3-30 13:06 作者: 培養(yǎng) 時(shí)間: 2025-3-30 19:30
Adnan Aydiner,Abdullah ?gci,Atilla SoranExhaustively reviews metastatic breast disease.Brings readers up to date with current breast.Provides a comprehensive account of the most recent.therapeutic regimens.Explores special therapeutic probl作者: Cumbersome 時(shí)間: 2025-3-30 23:25
http://image.papertrans.cn/b/image/190592.jpg作者: Affectation 時(shí)間: 2025-3-31 02:04 作者: 鑒賞家 時(shí)間: 2025-3-31 07:23 作者: committed 時(shí)間: 2025-3-31 11:02 作者: 跳動(dòng) 時(shí)間: 2025-3-31 14:57 作者: 性別 時(shí)間: 2025-3-31 20:10
